2H51 Stock Overview A clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Ocugen Historical stock prices Current Share Price US$0.81 52 Week High US$1.92 52 Week Low US$0.46 Beta 3.86 1 Month Change -3.51% 3 Month Change -6.84% 1 Year Change 52.16% 3 Year Change -78.02% 5 Year Change n/a Change since IPO -56.28%
Recent News & Updates
Ocugen, Inc. Receives A Notification Letter from Nasdaq Regarding Minimum Bid Price Jan 04
Ocugen, Inc. Announces Data and Safety Monitoring Board Reviewed Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Dec 19
Ocugen, Inc. Announces Compelling Preliminary Data for OCU410--Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Nov 20
Ocugen, Inc. Announces Executive Changes Nov 16
New major risk - Revenue and earnings growth Nov 12 Ocugen, Inc. announced that it has received $30 million in funding Nov 08
See more updates
Ocugen, Inc. Receives A Notification Letter from Nasdaq Regarding Minimum Bid Price Jan 04
Ocugen, Inc. Announces Data and Safety Monitoring Board Reviewed Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Dec 19
Ocugen, Inc. Announces Compelling Preliminary Data for OCU410--Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Nov 20
Ocugen, Inc. Announces Executive Changes Nov 16
New major risk - Revenue and earnings growth Nov 12 Ocugen, Inc. announced that it has received $30 million in funding Nov 08
Ocugen, Inc. to Report Q3, 2024 Results on Nov 08, 2024 Oct 17
Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for Ocu200 Phase 1 Clinical Trial Oct 09
Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa Aug 05
New minor risk - Shareholder dilution Aug 02 Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $35 million. Aug 02
Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $35 million.
Ocugen, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 29
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 Armada Clinical Trial of OCU410 —A Novel Modifier Gene Therapy Jul 25
Ocugen, Inc. Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease Jun 21
Ocugen, Inc. Announces First Patient Dosed in Phase 3 Limelight Clinical Trial for Ocu400—First Gene Therapy in Phase 3 with A Broad Retinitis Pigmentosa Indication Jun 20
Law Offices of Howard G. Smith Alleges Lawsuit Against Ocugen, Inc Jun 05
Ocugen, Inc. Announces Positive Outcome of the Data and Safety Monitoring Board Review for its Phase 1/2 ArMaDa Clinical Trial for OCU410 Jun 01
Ocugen, Inc., Annual General Meeting, Jun 28, 2024 May 21
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy May 16
Ocugen, Inc. Announces Ocu400 Modifier Gene Therapy Phase 1/2 Data Presentation At Retinal Cell and Gene Therapy Innovation Summit 2024 Apr 30
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410 --A Modifier Gene Therapy Apr 20 Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Ocugen, Inc
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial Apr 10
Ocugen, Inc. Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for Ocu410--A Modifier Gene Therapy-- in Phase 1/2 Armada Study for Geographic Atrophy Apr 05
Ocugen Provides Business Update Apr 03 Ocugen, Inc. to Report Q4, 2023 Results on Apr 02, 2024
Ocugen, Inc. Appoints Huma Qamar as Chief Medical Officer Mar 20
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410 Mar 14
Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST Feb 23
Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board Jan 16
Insufficient new directors Jan 01
Forecast to breakeven in 2026 Dec 31
Ocugen, Inc. Gains FDA Alignment on Key Aspects of OCU400 —Modifier Gene Therapy—Pivotal Phase 3 Study Design Dec 22
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—For Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration Dec 14
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST --Modifier Gene Therapy-- for Stargardt Disease Nov 11 Ocugen, Inc. to Report Q3, 2023 Results on Nov 09, 2023
Ocugen, Inc. Announces Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH NIAID Project NextGen for Inclusion in Clinical Trials Oct 11
Ocugen, Inc. Appoints Connie Collingsworth to the Business Advisory Board Sep 22
Ocugen, Inc. Announces Executive Changes Sep 21
Ocugen, Inc. Announces Positive Clinical Study Update from the Phase 1/2 Trial of Ocu400, A Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis Sep 14
Ocugen, Inc. to Report Q2, 2023 Results on Aug 21, 2023 Aug 19
Ocugen, Inc. announced delayed 10-Q filing Aug 17
Independent Director recently bought €92k worth of stock Jun 18
Ocugen, Inc. Announces Business Advisory Board Jun 06 Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $15 million. May 26
Ocugen, Inc. has completed a Follow-on Equity Offering. May 25
No longer forecast to breakeven Mar 03
Ocugen, Inc. to Report Q4, 2022 Results on Feb 28, 2023 Feb 16
Ocugen, Inc. Appoints Quan A. Vu as Chief Business Officer Feb 02
Ocugen, Inc. Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-Bridging and Broadening Study: Both Co-Primary Endpoints Met Jan 10
Forecast to breakeven in 2025 Dec 31
Ocugen, Inc Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis Dec 08
High number of new directors Nov 16
Ocugen, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Oct 28
Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2 Oct 13
Ocugen, Inc. Announces Publication of Comprehensive Review of BBV152 in Frontiers in Immunology Sep 15
Ocugen, Inc. Announces Board Changes Sep 02
No longer forecast to breakeven Aug 14
Ocugen, Inc. to Report Q2, 2022 Results on Aug 05, 2022 Jul 30
Ocugen, Inc. Announces Publication of Positive Results of Covid-19 Vaccine Trial for Children 2 18 in the Lancet Infectious Diseases Jun 22
Ocugen, Inc. Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition May 26
Ocugen, Inc. Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition May 25
Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for Covaxin (Bbv152) May 24
Forecast breakeven date pushed back to 2023 May 14
Ocugen, Inc. to Report Q1, 2022 Results on May 06, 2022 May 03
High number of new and inexperienced directors Apr 27
Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial Apr 26
Ocugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN™ (BBV152) Apr 13
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration Apr 03
Ocugen, Inc. Announces Resignation of Sanjay S. Subramanian as Chief Financial Officer Mar 07 Ocugen, Inc. Provides Update on its COVAXIN™ Pediatric (2-18) Emergency Use Authorization Request
Forecast breakeven date pushed back to 2023 Mar 05
Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $53.5 million. Feb 25 Ocugen, Inc. has completed a Follow-on Equity Offering in the amount of $53.5 million. Feb 24
Shareholder Returns 2H51 DE Biotechs DE Market 7D -4.6% 6.0% 1.7% 1Y 52.2% -5.6% 9.4%
See full shareholder returns
Return vs Market: 2H51 exceeded the German Market which returned 9.6% over the past year.
Price Volatility Is 2H51's price volatile compared to industry and market? 2H51 volatility 2H51 Average Weekly Movement 10.9% Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 2H51's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2H51's weekly volatility has decreased from 19% to 11% over the past year, but is still higher than 75% of German stocks.
About the Company Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult.
Show more Ocugen, Inc. Fundamentals Summary How do Ocugen's earnings and revenue compare to its market cap? 2H51 fundamental statistics Market cap €247.47m Earnings (TTM ) -€49.59m Revenue (TTM ) €4.56m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2H51 income statement (TTM ) Revenue US$4.70m Cost of Revenue US$31.62m Gross Profit -US$26.91m Other Expenses US$24.23m Earnings -US$51.14m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.18 Gross Margin -572.66% Net Profit Margin -1,088.17% Debt/Equity Ratio 7.1%
How did 2H51 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/08 03:39 End of Day Share Price 2025/01/08 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Ocugen, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Kristen Kluska Cantor Fitzgerald & Co. Daniil Gataulin Chardan Capital Markets, LLC Swayampakula Ramakanth H.C. Wainwright & Co.
Show 3 more analysts 
